Genomenon is proud to be the variant interpretation tool that leading clinical decision support platforms use to provide easy access to the most comprehensive collection of published genomic evidence. Today we celebrate our 13th integration with eVai, created by enGenome.By combining artificial intelligence with ACMG-AMP guidelines, eVai classifies and prioritizes every genomic variant for pathogenicity, suggesting all the possible related genetic diagnoses. The accurate prioritization combined with an unique and intuitive interface allows researchers to focus on the smallest interesting set of variants.
Genomenon Partners with enGenome to Improve Variant Interpretation Accuracy and Speed
enGenome Integrates Mastermind Genomic Search Engine into eVai Variant Interpretation Platform
Genomenon® announced a partnership with enGenome, which includes integration of the Mastermind® Genomic Search Engine into the eVai Variant Interpretation platform. eVai users can now preview the number of published articles related to their search and easily link out to view the evidence in Mastermind.
Genomenon’s Mastermind is the world’s only comprehensive genomic search engine, connecting patient’s genomic data with evidence from the scientific literature – a key requirement in analyzing a patient’s DNA in precision medicine for cancer and genetic diseases. Mastermind has indexed over 7.5 million full text articles and 1.5 million supplemental data sets and covers over 6.1 million variants found in the medical literature.
By combining artificial intelligence with ACMG-AMP guidelines, eVai classifies and prioritizes every genomic variant for pathogenicity, suggesting all the possible related genetic diagnoses. The accurate prioritization combined with an unique and intuitive interface allows researchers to focus on the smallest interesting set of variants.
“Integrating Mastermind into eVai gives our users access to the premier source of genomic association data, which is an essential element of variant interpretation.” Said Dr. Ettore Rizzo, CEO of enGenome. “We are thrilled to be partnering with Genomenon in this way, particularly since we both use A.I. in ground-breaking ways.”
“We’re excited to partner with enGenome to put the most comprehensive and up-to-date genomic research in the hands of geneticists and researchers performing genomic analysis.” said Mike Klein, CEO of Genomenon. “Our relationship extends Mastermind’s global reach, and coupled with eVai, provides significant value in cutting turnaround time and increasing diagnostic yield for genetic labs.”
Read our blog post on how to find Mastermind genomic evidence from eVai.
Genomenon is a genomic health IT company that connects patient DNA with the billions of dollars spent on research to help doctors diagnose and cure cancer patients and babies with rare diseases.
The Mastermind Genomic Search Engine is used by hundreds of genetic labs worldwide to accelerate diagnosis, increase diagnostic yield, and assure repeatability in reporting genetic testing results.
Mastermind Genomic LandscapesTM inform pharmaceutical and bio-pharma companies on precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx regulatory submissions with empirical evidence.
Genomenon was named 2020 Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan.
Candace Chapman 1-734-219-5175 email@example.com
enGenome is a digital health company that provides the experience and software technology for the analysis and interpretation of genomic data in clinical and research settings, thus enabling healthcare providers to unleash the potential of Precision Medicine.
The eVai platform, created by enGenome, combines ACMG automation and variant prioritization to interpret genomic variants with an unprecedented accuracy and speed. eVai is a cloud-based platform CE IVD marked and used in the clinical routine for diagnosis purposes.
enGenome is an academic spin-off of the University of Pavia and leverages on its core competencies related to Bioinformatics and Artificial Intelligence to work toward the mission of delivering the most accurate genomic interpretation to diagnose and treat genetic diseases.
For more information, visit engenome.com